Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BXQ 350

Next Previous
Drug Profile

BXQ 350

Alternative Names: BXQ-350; SapC; SapC-DOPS; SapC-DOPS nanovesicles; Saposin C–dioleoylphosphatidylserine complexes; Sphingolipid activator protein C

Latest Information Update: 25 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bexion Pharmaceuticals
  • Developer Bexion Pharmaceuticals; Cincinnati Children's Hospital Medical Center
  • Class Antineoplastics; Antiparkinsonians; Phosphatidylserines; Saposins; Tumour-agnostic therapies
  • Mechanism of Action Sphingomyelin phosphodiesterase stimulants; Sphingosine 1-phosphate stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Glioblastoma; Glioma; Peripheral nervous system diseases
  • Phase 0 Peripheral neuropathies
  • Preclinical CNS disorders; Parkinson's disease; Viral infections
  • No development reported Solid tumours

Most Recent Events

  • 14 Nov 2024 Preclinical trials in Parkinson's disease in USA (unspecified route)
  • 05 Nov 2024 Bexion Pharmaceuticals completes enrolment in the phase-0 RETRO trial for Peripheral neuropathies in USA (NCT05291286),
  • 04 Oct 2024 Bexion Pharmaceuticals terminates a phase I trial in Glioma (In children, In adolescents, In adults) in USA (IV) as Bexion Pharmaceuticals has decided to close the BXQ-350.AD study to enrollment prior to the anticipated enrollment goal (NCT04771897)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top